[1]
|
Obradovic, M., et al. (2019) Effects of IGF-1 on the Cardiovascular System. Current Pharmaceutical Design, 25, 3715-3725. https://doi.org/10.2174/1381612825666191106091507
|
[2]
|
Higashi, Y., Gautam, S., Delafontaine, P. and Sukhanov, S. (2019) IGF-1 and Cardiovascular Disease. Growth Hormone & IGF Research, 45, 6-16. https://doi.org/10.1016/j.ghir.2019.01.002
|
[3]
|
Springer, J., Springer, J.I. and Anker, S.D. (2017) Muscle Wasting and Sarcopenia in Heart Failure and Beyond: Update 2017. ESC Heart Failure, 4, 492-498. https://doi.org/10.1002/ehf2.12237
|
[4]
|
Oldham, S. and Hafen, E. (2003) Insulin/IGF and Target of Rapamycin Signaling: A TOR de Force in Growth Control. Trends in Cell Biology, 13, 79-85. https://doi.org/10.1016/S0962-8924(02)00042-9
|
[5]
|
Lisowska, A., et al. (2019) Insulin-Like Growth Fac-tor-Binding Protein 7 (IGFBP 7) as a New Biomarker in Coronary Heart Disease. Advances in Medical Sciences, 64, 195-201. https://doi.org/10.1016/j.advms.2018.08.017
|
[6]
|
Chen, D., et al. (2011) Insulin-Like Growth Fac-tor-Binding Protein-7 Functions as a Potential Tumor Suppressor in Hepatocellular Carcinoma. Clinical Cancer Research, 17, 6693-6701.
https://doi.org/10.1158/1078-0432.CCR-10-2774
|
[7]
|
王燕, 等, 胰岛素样生长因子结合蛋白-7在射血分数保留心衰病人中的表达及临床意义[J]. 实用老年医学, 2018, 32(12): 1129-1133.
|
[8]
|
乐建华, 等, 血清IGFBP7水平对射血分数中间范围型心力衰竭患者心脏舒张功能障碍的评估价值[J]. 广东医科大学学报, 2018, 36(6): 668-670.
|
[9]
|
Gandhi, P.U., et al. (2017) Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. Journal of Cardiac Failure, 23, 20-28.
https://doi.org/10.1016/j.cardfail.2016.06.006
|
[10]
|
Kalayci, A., et al. (2020) Echocardiographic Assessment of In-sulin-Like Growth Factor Binding Protein-7 and Early Identification of Acute Heart Failure. ESC Heart Failure, 7, 1664-1675. https://doi.org/10.1002/ehf2.12722
|
[11]
|
Gandhi, P.U., et al. (2016) Insulin-Like Growth Fac-tor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure with Preserved Ejection Fraction: Results From the RELAX Trial. JACC: Heart Fail, 4, 860-869. https://doi.org/10.1016/j.jchf.2016.08.002
|
[12]
|
Januzzi, J.J., et al. (2018) IGFBP7 (Insulin-Like Growth Fac-tor-Binding Protein-7) and Neprilysin Inhibition in Patients with Heart Failure. Circulation: Heart Failure, 11, e005133.
https://doi.org/10.1161/CIRCHEARTFAILURE.118.005133
|
[13]
|
Ruan, W., et al. (2017) Serum Levels of IGFBP7 Are Elevated during Acute Exacerbation in COPD Patients. International Journal of Chronic Obstructive Pul-monary Disease, 12, 1775-1780. https://doi.org/10.2147/COPD.S132652
|
[14]
|
Bracun, V., et al. (2022) Insu-lin-Like Growth Factor Binding Protein 7 (IGFBP7), a Link between Heart Failure and Senescence. ESC Heart Failure, 9, 4167-4176. https://doi.org/10.1002/ehf2.14120
|
[15]
|
Iwahana, H., et al. (1999) Different Promoter Usage and Multiple Transcription Initiation Sites of the Interleukin-1 Receptor-Related Human ST2 Gene in UT-7 and TM12 Cells. European Journal of Biochemistry, 264, 397-406.
https://doi.org/10.1046/j.1432-1327.1999.00615.x
|
[16]
|
Xiang, N., et al. (2021) Expression and Significance of In-flammatory Reactions Mediated by the IL-33/ST2 Signaling Pathway in the Serum of Heart Failure Patients. American Journal of Translational Research, 13, 8247-8252.
|
[17]
|
Yang, C., et al. (2021) The Diagnostic Value of Soluble ST2 in Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 8, Article 685904. https://doi.org/10.3389/fcvm.2021.685904
|
[18]
|
Lotierzo, M., Dupuy, A.M., Kalmanovich, E., Roubille, F. and Cristol, J.P. (2020) sST2 as a Value-Added Biomarker in Heart Failure. Clinica Chimica Acta, 501, 120-130.
https://doi.org/10.1016/j.cca.2019.10.029
|
[19]
|
Li, J., et al. (2021) A Review of Novel Cardiac Biomarkers in Acute or Chronic Cardiovascular Diseases: The Role of Soluble ST2 (sST2), Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO) and Procalcitonin (PCT). Disease Markers, 2021, Article ID: 6258865. https://doi.org/10.1155/2021/6258865
|
[20]
|
Ky, B., et al. (2011) High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation: Heart Failure, 4, 180-187. https://doi.org/10.1161/CIRCHEARTFAILURE.110.958223
|
[21]
|
Dings, R., et al. (2018) Galectins as Molecular Targets for Therapeutic Intervention. International Journal of Molecular Sciences, 19, Article 905. https://doi.org/10.3390/ijms19030905
|
[22]
|
Blanda, V., et al. (2020) Galectin-3 in Cardiovascular Diseases. Inter-national Journal of Molecular Sciences, 21, Article 9232. https://doi.org/10.3390/ijms21239232
|
[23]
|
Sharma, U.C., et al. (2004) Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction. Circulation, 110, 3121-3128. https://doi.org/10.1161/01.CIR.0000147181.65298.4D
|
[24]
|
Ho, J.E., et al. (2012) Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. Journal of the American College of Cardiology, 60, 1249-1256. https://doi.org/10.1016/j.jacc.2012.04.053
|
[25]
|
Li, P., et al. (2016) Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance. Cell, 167, 973-984. https://doi.org/10.1016/j.cell.2016.10.025
|
[26]
|
Yu, L., et al. (2013) Genetic and Pharmacological Inhibition of Ga-lectin-3 Prevents Cardiac Remodeling by Interfering with Myocardial Fibrogenesis. Circulation: Heart Failure, 6, 107-117.
https://doi.org/10.1161/CIRCHEARTFAILURE.112.971168
|
[27]
|
Ueland, T., et al. (2011) Galectin-3 in Heart Failure: High Levels Are Associated with All-Cause Mortality. International Journal of Cardiology, 150, 361-364.
|
[28]
|
Yin, Q.-S., Shi, B., Dong, L. and Bi, L. (2014) Comparative Study of Galectin-3 and B-Type Natriuretic Peptide as Biomarkers for the Diagnosis of Heart Failure. Journal of Geriatric Cardiology, 11, 79-82.
|
[29]
|
Trippel, T.D., et al. (2021) The Diagnostic and Prognostic Value of Galectin-3 in Patients at Risk for Heart Failure with Preserved Ejec-tion Fraction: Results from the DIAST-CHF Study. ESC Heart Failure, 8, 829-841.
https://doi.org/10.1002/ehf2.13174
|
[30]
|
Lok, D.J., Lok, S.I., de la Porte, P.W.B.-A., Badings, E., Lipsic, E., van Wijngaarden, J., de Boer, R.A., van Veldhuisen, D.J. and van der Meer, P. (2013) Galectin-3 Is an Independent Marker for Ventricular Remodeling and Mortality in Patients with Chronic Heart Failure. Clinical Research in Cardiology, 102, 103-110.
https://doi.org/10.1007/s00392-012-0500-y
|
[31]
|
Grandin, E.W., et al. (2012) Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22. Clinical Chemistry, 58, 267-273. https://doi.org/10.1373/clinchem.2011.174359
|
[32]
|
Fermann, G.J., et al. (2012) Galectin 3 Complements BNP in Risk Stratification in Acute Heart Failure. Biomarkers, 17, 706-713. https://doi.org/10.3109/1354750X.2012.719037
|
[33]
|
Shi, Y., et al. (2022) Clinical Implications of Plasma Galec-tin-3 in Heart Failure with Preserved Ejection Fraction: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 9, Arti-cle 854501. https://doi.org/10.3389/fcvm.2022.854501
|
[34]
|
Špinar, J., Špinarová, L. and Vítovec, J. (2018) Path-ophysiology, Causes and Epidemiology of Chronic Heart Failure. Vnitrní Lékarství, 64, 834-838. https://doi.org/10.36290/vnl.2018.114
|
[35]
|
Maalouf, R. and Bailey, S. (2016) A Review on B-Type Natriuretic Peptide Monitoring: Assays and Biosensors. Heart Failure Reviews, 21, 567-578. https://doi.org/10.1007/s10741-016-9544-9
|
[36]
|
Kurmani, S. and Squire, I. (2017) Acute Heart Failure: Definition, Classification and Epidemiology. Current Heart Failure Reports, 14, 385-392. https://doi.org/10.1007/s11897-017-0351-y
|
[37]
|
Mueller, C., et al. (2019) Heart Failure Association of the Euro-pean Society of Cardiology Practical Guidance on the Use of Natriuretic Peptide Concentrations. European Journal of Heart Failure, 21, 715-731.
https://doi.org/10.1002/ejhf.1494
|
[38]
|
Ponikowski, P., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 18, 891-975. https://doi.org/10.1002/ejhf.592
|
[39]
|
Castiglione, V., Aimo, A., Vergaro, G., Saccaro, L., Passino, C. and Emdin, M. (2022) Biomarkers for the Diagnosis and Management of Heart Failure. Heart Failure Reviews, 27, 625-643. https://doi.org/10.1007/s10741-021-10105-w
|
[40]
|
Wieczorek, S.J., et al. (2002) A Rapid B-Type Natriuretic Pep-tide Assay Accurately Diagnoses Left Ventricular Dysfunction and Heart Failure: A Multicenter Evaluation. American Heart Journal, 144, 834-839.
https://doi.org/10.1067/mhj.2002.125623
|
[41]
|
Masarone, D., et al. (2017) Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. Pediatrics and Neonatology, 58, 303-312. https://doi.org/10.1016/j.pedneo.2017.01.001
|
[42]
|
Redfield, M.M., et al. (2013) Effect of Phosphodiesterase-5 In-hibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction: A Randomized Clini-cal Trial. JAMA, 309, 1268-1277.
https://doi.org/10.1001/jama.2013.2024
|
[43]
|
Olsen, M.B., et al. (2022) Targeting the Inflammasome in Cardiovas-cular Disease. JACC: Basic to Translational Science, 7, 84-98. https://doi.org/10.1016/j.jacbts.2021.08.006
|
[44]
|
Crespo-Leiro, M.G., et al. (2018) Advanced Heart Failure: A Po-sition Statement of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 20, 1505-1535. https://doi.org/10.1002/ejhf.1236
|
[45]
|
Alonso-Martínez, J.L., Llorente-Diez, B., Eche-garay-Agara, M., Olaz-Preciado, F., Urbieta-Echezarreta, M. and González-Arencibia, C. (2002) C-Reactive Protein as a Predictor of Improvement and Readmission in Heart Failure. European Journal of Heart Failure, 4, 331-336. https://doi.org/10.1016/S1388-9842(02)00021-1
|
[46]
|
Parikh, K.S., et al. (2018) Heart Failure with Preserved Ejec-tion Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. JACC: Basic to Transla-tional Science, 6, 619-632.
https://doi.org/10.1016/j.jchf.2018.06.008
|
[47]
|
Nakayama, H. and Otsu, K. (2013) Translation of Hemodynamic Stress to Sterile Inflammation in the Heart. Trends in Endocrinology & Metabolism, 24, 546-553. https://doi.org/10.1016/j.tem.2013.06.004
|
[48]
|
Park, J.J., et al. (2022) C-Reactive Protein and Statins in Heart Fail-ure with Reduced and Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 9, Article 1064967. https://doi.org/10.3389/fcvm.2022.1064967
|
[49]
|
Røsjø, H., Husberg, C., Dahl, M.B., Stridsberg, M., Sjaastad, I., Finsen, A.V., Carlson, C.R., Øie, E., Omland, T. and Christensen, G. (2010) Chromogranin B in Heart Failure: A Puta-tive Cardiac Biomarker Expressed in the Failing Myocardium. Circulation: Heart Failure, 3, 503-511. https://doi.org/10.1161/CIRCHEARTFAILURE.109.867747
|
[50]
|
Egerstedt, A., et al. (2022) Bioactive Adreno-medullin for Assessment of venous Congestion in Heart Failure. ESC Heart Failure, 9, 3543-3555. https://doi.org/10.1002/ehf2.14018
|
[51]
|
Voors, A.A., et al. (2019) Adrenomedullin in Heart Failure: Pathophysi-ology and Therapeutic Application. European Journal of Heart Failure, 21, 163-171. https://doi.org/10.1002/ejhf.1366
|
[52]
|
Maisel, A., et al. (2010) Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea: Results from the BACH (Biomarkers in Acute Heart Failure) Trial. Journal of the American College of Cardiology, 55, 2062-2076. https://doi.org/10.1016/j.jacc.2010.02.025
|
[53]
|
Bronton, K., Wessman, T., Gränsbo, K., Schulte, J., Hartmann, O. and Melander, O. (2022) Bioactive Adrenomedullin a Prognostic Biomarker in Patients with Mild to Moderate Dyspnea at the Emergency Department: An Observational Study. Internal and Emergency Medicine, 17, 541-550. https://doi.org/10.1007/s11739-021-02776-y
|
[54]
|
Shah, R.V., Truong, Q.A., Gaggin, H.K., Pfannkuche, J., Hartmann, O. and Januzzi, J.L. (2012) Mid-Regional Pro-Atrial Natriuretic Peptide and Pro-Adrenomedullin Testing for the Diagnostic and Prognostic Evaluation of Patients with Acute Dyspnoea. Euro-pean Heart Journal, 33, 2197-2205. https://doi.org/10.1093/eurheartj/ehs136
|
[55]
|
Chatterjee, K. (2005) Neuro-hormonal Activation in Congestive Heart Failure and the Role of Vasopressin. The American Journal of Cardiology, 95, 8-13. https://doi.org/10.1016/j.amjcard.2005.03.003
|
[56]
|
Sparapani, S., et al. (2021) The Biology of Vasopressin. Biomedicines, 9, Article 89.
|
[57]
|
Maisel, A., et al. (2011) Increased 90-Day Mortality in Patients with Acute Heart Fail-ure with Elevated Copeptin: Secondary Results from the Biomarkers in Acute Heart Failure (BACH) Study. Circulation: Heart Failure, 4, 613-620.
https://doi.org/10.1161/CIRCHEARTFAILURE.110.960096
|
[58]
|
Zhong, Y., Wang, R., Yan, L., Lin, M., Liu, X. and You, T. (2017) Copeptin in Heart Failure: Review and Meta-Analysis. Clinica Chimica Acta, 475, 36-43. https://doi.org/10.1016/j.cca.2017.10.001
|